Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed adenocarcinoma of the pancreas~* Locally advanced or metastatic disease that is considered unresectable~* No known CNS metastases~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* ECOG 0-2~Life expectancy:~* Not specified~Hematopoietic:~* Absolute granulocyte count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin less than 2 times upper limit of normal (ULN)~* AST and/or ALT less than 2 times ULN (5 times ULN if liver metastases present)~Renal:~* Creatinine less than 1.5 times ULN~Cardiovascular:~* No uncontrolled high blood pressure~* No unstable angina~* No congestive heart failure~* No myocardial infarction within the past year~* No cardiac ventricular arrhythmias requiring medication~Gastrointestinal:~* No gastrointestinal (GI) tract disease resulting in an inability to take oral medication such as uncontrolled inflammatory GI disease (e.g., Crohn's disease or ulcerative colitis)~* No post-surgical malabsorption characterized by:~  * Uncontrolled diarrhea that results in weight loss and vitamin deficiency OR~ * Requires IV hyperalimentation~ * Pancreatic enzyme supplementation allowed provided that the above criteria are not met~Ophthalmic:~* No ocular inflammation or infection unless fully treated prior to study~* No significant ophthalmologic abnormalities, including the following:~  * Severe dry eye syndrome~ * Sjogren's syndrome~ * Keratoconjunctivitis sicca~ * Severe exposure keratopathy~ * Disorders that would increase the risk for epithelium-related complications (e.g., bullous keratopathy, aniridia, severe chemical burns, or neutrophilic keratitis)~Other:~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* HIV negative~* No serious active infection~* No other serious underlying medical, psychological, or geographical condition that would preclude study participation~* No prior allergic reaction to compounds with similar chemical or biologic composition to erlotinib~* No other prior malignancy within the past 5 years except cancer in situ or basal cell or squamous cell skin cancer~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No concurrent biologic therapy or immunotherapy~Chemotherapy:~* No prior chemotherapy except fluorouracil (with or without leucovorin calcium) or gemcitabine administered concurrently with radiotherapy as a radiosensitizer~* No other concurrent cytotoxic chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* See Chemotherapy~* At least 4 weeks since prior radiotherapy and recovered~* Prior radiotherapy for local disease allowed if evidence of disease progression has occurred~* No concurrent radiotherapy~Surgery:~* See Disease Characteristics~* At least 2 weeks since prior major surgery~* No concurrent ophthalmic surgery~Other:~* No prior epidermal growth factor receptor inhibitors~* At least 2 weeks since prior investigational drug~* No other concurrent investigational drugs during and for at least 30 days after study~* No other concurrent anti-cancer therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- OSI-774 plus Gemcitabine (Type: ACTIVE_COMPARATOR): None
- Placebo plus gemcitabine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete